Anti-Coagulants - Malta

Malta

In Malta, the revenue in the Anti-Coagulants market is projected to reach US$4.86m in 2024.
This is expected to show an annual growth rate (CAGR 2024-2029) of 8.27%, resulting in a market volume of US$7.23m by 2029.
When comparing globally, it is worth noting that United States is expected to generate the most revenue, with US$16,740.00m in 2024.
The demand for anti-coagulants in Malta has surged due to the country's aging population and high prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The use of Anti-Coagulants in Malta has been on the rise in recent years.

Customer preferences: Patients in Malta are increasingly opting for Anti-Coagulants as a treatment option for various conditions such as deep vein thrombosis, pulmonary embolism, and stroke prevention. This trend is in line with the global market, where the demand for Anti-Coagulants is increasing due to the growing prevalence of cardiovascular diseases and an aging population.

Trends in the market: The Anti-Coagulants market in Malta is dominated by oral anticoagulants, which are preferred by patients due to their convenience and ease of administration. The market is also witnessing an increase in the adoption of direct oral anticoagulants (DOACs) as they offer several advantages over traditional anticoagulants such as warfarin, including fewer drug interactions and the absence of a need for frequent monitoring. The market for DOACs is expected to continue to grow in the coming years.

Local special circumstances: Malta has a high prevalence of cardiovascular diseases, which is driving the demand for Anti-Coagulants. Additionally, the country has a rapidly aging population, which is also contributing to the growth of the market.

Underlying macroeconomic factors: The Maltese healthcare system is well-developed, with the government providing universal healthcare coverage to its citizens. This has enabled patients to access Anti-Coagulants easily, contributing to the growth of the market. Furthermore, the Maltese government has been investing in the healthcare sector, which is expected to drive the growth of the Anti-Coagulants market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.